Icelandic biotech company Alvotech has received approval from the US Food and Drug Administration, FDA, for a new manufacturing process for the biosimilar Simlandi, a counterpart to Humira. This is stated in a press release.
The new process makes it possible to more than double the production of drug substance per manufacturing batch at the company’s facility in Reykjavik, without increasing the manufacturing scale. The product’s quality, safety and efficacy are maintained.
“The new process enables us to manufacture the same amount of drug substance in fewer batches, freeing up capacity for other products in our portfolio, resulting in better utilization of our existing infrastructure and giving us greater flexibility to meet growing demand,” says Joseph McClellan, CEO and Chief Operating Officer of Alvotech.